Everolimus tablets for patients with subependymal giant cell astrocytoma

Bibliography

• Krueger DA, Franz DN. Current management of tuberous sclerosis complex. Paediatr Drugs 2008;10:299-313
   PubMedGoogle Scholar
• Braffman BH, Bilaniuk LT, Naidich TP, MR imaging of tuberous sclerosis: pathogenesis of this phakomatosis, use of gadopentetate dimeglumine, and literature review. Radiology 1992;183:227-38
   PubMed Web of Science ®Google Scholar
• Nabbout R, Santos M, Rolland Y, Early diagnosis of subependymal giant cell astrocytoma in children with tuberous sclerosis. J Neurol Neurosurg Psychiatry 1999;66:370-5
   Google Scholar
• Cuccia V, Zuccaro G, Sosa F, Subependymal giant cell astrocytoma in children with tuberous sclerosis. Childs Nerv Syst 2003;19:232-43
   PubMed Web of Science ®Google Scholar
• Adriaensen ME, Schaefer-Prokop CM, Stijnen T, Prevalence of subependymal giant cell tumors in patients with tuberous sclerosis and a review of the literature. Eur J Neurol 2009;16:691-6
   PubMed Web of Science ®Google Scholar
• Franz DN, de Vries PJ, Crino PB. Giant cell astrocytomas in tuberous sclerosis complex. Arch Dis Child 2009;94:75-6
   Google Scholar
• Roach ES, Gomez MR, Northrup H. Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J Child Neurol 1998;13:624-8
   PubMed Web of Science ®Google Scholar
• Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med 2006;355:1345-56
   PubMed Web of Science ®Google Scholar
• van Slegtenhorst M, de Hoogt R, Hermans C, Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997;277:805-8
   PubMed Web of Science ®Google Scholar
• The European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 1993;75:1305-15
   PubMed Web of Science ®Google Scholar
• Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004;18:1926-45
   PubMed Web of Science ®Google Scholar
• Inoki K, Li Y, Xu T, Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 2003;17:1829-34
   PubMed Web of Science ®Google Scholar
• Benvenuto G, Li S, Brown SJ, The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination. Oncogene 2000;19:6306-16
   PubMed Web of Science ®Google Scholar
• Henry KW, Yuan X, Koszewski NJ, Tuberous sclerosis gene 2 product modulates transcription mediated by steroid hormone receptor family members. J Biol Chem 1998;273:20535-9
   PubMed Web of Science ®Google Scholar
• Chan JA, Zhang H, Roberts PS, Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. J Neuropathol Exp Neurol 2004;63:1236-42
   PubMed Web of Science ®Google Scholar
• Huang J, Manning BD. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J 2008;412:179-90
   PubMed Web of Science ®Google Scholar
• Easton JB, Houghton PJ. mTOR and cancer therapy. Oncogene 2006;25:6436-46
   PubMed Web of Science ®Google Scholar
• Franz DN, Leonard J, Tudor C, Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 2006;59:490-8
   PubMed Web of Science ®Google Scholar
• Koenig MK, Butler IJ, Northrup H. Regression of subependymal giant cell astrocytoma with rapamycin in tuberous sclerosis complex. J Child Neurol 2008;23:1238-9
   PubMed Web of Science ®Google Scholar
• Plas DR, Thomas G. Tubers and tumors: rapamycin therapy for benign and malignant tumors. Curr Opin Cell Biol 2009;21:230-6
   PubMed Web of Science ®Google Scholar
• Kenerson H, Dundon TA, Yeung RS. Effects of rapamycin in the Eker rat model of tuberous sclerosis complex. Pediatr Res 2005;57:67-75
   PubMed Web of Science ®Google Scholar
• Bissler JJ, McCormack FX, Young LR, Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008;358:140-51
   PubMed Web of Science ®Google Scholar
• Houghton PJ. Everolimus. Clin Cancer Res 2010;16:1368-72
   PubMed Web of Science ®Google Scholar
• Krueger DA, Care MM, Holland K, Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010;363:1801-11
   PubMed Web of Science ®Google Scholar
• Chang SM, Kuhn J, Wen P, Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Investigational New Drugs 2004:22;427-35
   PubMed Web of Science ®Google Scholar
• Chang SM, Wen P, Cloughesy T, Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Investigational New Drugs 2005:23;357-61
   PubMed Web of Science ®Google Scholar
• Galanis E, Buckner JC, Maurer MJ, Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group Study. J Clin Oncol 2005:23;5294-304
   PubMed Web of Science ®Google Scholar
• Cloughesy TF, Yoshimoto K, Nghiemphu P, Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLOS Medicine V.5(1):e8, 2008, Jan 22
   Google Scholar
• Carracedo A, Ma L, Teruya-Feldstein J, Inhibition of MTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008:118;3065-74
   PubMed Web of Science ®Google Scholar
• Niyazi M, Siefert A, Schwarz SB, Therapeutic options for recurrent malignant glioma. Radiother Oncol 2011;98:1-14
   Google Scholar
• Van Meir EG, Hadjipanayis CG, Norden AD, Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 2010;60:166-93
   PubMed Web of Science ®Google Scholar